Direct answer. Medicines for heart-rhythm problems can slow the heart rate, help maintain or restore a rhythm, or serve a separate clot-prevention purpose. The appropriate prescription depends on the diagnosed arrhythmia and the heart’s structure and function. Some rhythm medicines can also cause a dangerous rhythm or other organ problems, so monitoring and a clear symptom/action plan matter. Do not make routine dose or treatment changes independently; follow specific urgent medicine warnings. Confidence is high in these distinctions, while an independent best-drug ranking is not established here. NHLBI selected AF rate, rhythm and clot-prevention distinctions, November2022; MHRA amiodarone safety and monitoring notice, updated May20,2026.
- Rate control, rhythm control and clot prevention are separate goals.
- A pulse or smartwatch alert alone cannot select the correct rhythm medicine.
- Sotalol, digoxin and amiodarone have different monitoring requirements.
- New medicines, electrolyte changes and kidney-function changes can affect safety.
- Palpitations with faintness, chest pain or serious breathing difficulty need emergency assessment.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Is a slower pulse the same as restoring rhythm? | Public AF framework | No. Rate control and rhythm control are different goals. |
| Do rhythm medicines replace AF anticoagulation? | Selected clot-prevention distinction | No automatic replacement; stroke-prevention assessment remains separate. |
| Can treatment itself worsen a rhythm? | Public safety context | Yes. Medicine choice, interactions and monitoring matter. |
| Does amiodarone need symptom review after stopping? | Regulator toxicity notice | Yes. Effects can persist; follow the agreed safety plan. |
| Are electrolyte supplements a general cure? | Human-evidence boundary | No. Correcting a measured deficiency differs from unsupervised supplementation. |
Confidence is high in the rate/rhythm/clot-prevention distinctions and monitoring/urgent-review principles; selecting or changing treatment requires the diagnosed rhythm and specialist assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What rhythm medicines treat and why diagnosis comes first
“Antiarrhythmic” commonly refers to medicines used to manage abnormal heart rhythms. Related prescriptions may chiefly slow the ventricular rate rather than restore a normal rhythm. Ask the clinician to name the goal, not simply say the tablet is “for the heart.” NHLBI selected AF rate, rhythm and clot-prevention distinctions, November2022.
An arrhythmia diagnosis requires appropriate clinical assessment. ECG recordings, longer monitoring, blood tests or assessment of heart structure can help identify the problem. Similar sensations can arise from different rhythms, so a racing-heart episode is not a reason to borrow another person’s medicine. NHLBI rhythm diagnosis and selected monitoring tests, March2022.
This guide covers treatment questions and safety. Emergency injection treatment, a personalized drug-selection algorithm and an exhaustive international medicine-availability list are outside its scope.
Rate control, rhythm control and clot prevention
Rate control aims to manage how quickly the heart pumps, while an abnormal rhythm may continue. Rhythm control aims to restore or maintain a chosen rhythm. For AF, preventing stroke is another task that can require anticoagulation. A symptom improvement does not by itself show that the anticoagulation indication has ended. NHLBI selected AF rate, rhythm and clot-prevention distinctions, November2022.
Medicine families act differently on electrical activity or the heart’s response to nerve signals. Sodium-channel medicines include flecainide; potassium-channel medicines include sotalol and amiodarone. Some medicines have more than one relevant action, so a class label is not a complete description of suitability. NHS selected sotalol mechanism and procedure questions, August5,2025.
Beta blockers can slow the heartbeat and are used in several cardiac situations. Names such as bisoprolol, metoprolol and sotalol should not be treated as interchangeable prescriptions. A medicine’s use for another diagnosis does not establish that it suits a particular arrhythmia. NHS beta blockers, actual September4,2026 original.
Medicine families, specialist choice and procedure options
Selection depends on the exact rhythm, symptoms and relevant heart disease. Some treatments may worsen a slow rhythm or conduction problem; other suitability questions concern heart function, kidney health or breathing disease. A simplified online contraindication list cannot replace that assessment. NHS sotalol suitability factors, August5,2025.
Digoxin is a cardiac glycoside used in selected heart problems, including AF rate management. It is not a general replacement for every rhythm-control drug. The opened NHS guide also describes use alongside other heart-failure treatment; this dated educational statement is not a complete current heart-failure treatment menu. NHS digoxin mechanism and selected monitoring, March22,2023, review overdue.
Amiodarone requires specialist initiation and supervision because it can affect several organs. The regulator describes use when other treatment cannot be used or has failed. That is attributed clinical context, not a claim that it is the independently proven best option for everyone. MHRA amiodarone safety and monitoring notice, updated May20,2026.
Cardioversion, ablation, pacemakers and ICDs address different problems and may be considered alongside medicine. Do not infer that every procedure must wait until every drug has failed, or that a device removes the need for all medicine. Discuss the actual options and treatment goal. NHLBI arrhythmia medicine/procedure mechanisms, March2022.
Electrolytes, supplements, triggers and supportive care
There is no financially screened supplement regimen here that replaces prescribed rhythm treatment. The fact that a nutrient affects cardiac cells does not prove that taking more prevents dangerous arrhythmias or reduces mortality in people.
Potassium and magnesium levels can matter, but the appropriate response to an abnormal result requires clinical assessment. The NHS sotalol original emphasizes kidney and electrolyte monitoring. Do not self-prescribe an electrolyte product or interpret an isolated laboratory result as a dose instruction. NHS sotalol purpose and blood monitoring, August5,2025.
Herbal and complementary products have incomplete combination-safety data with sotalol. “Natural” does not provide interaction clearance. Give the pharmacist actual ingredient names, amounts and product labels, including products marketed for sleep, stress, energy or circulation. NHS sotalol medicine/supplement interactions, August5,2025.
Activity, alcohol, smoking support and care for contributing illnesses need an individualized plan. Report patterns in symptoms without assuming every episode proves a particular trigger. Psychological support can help with fear or distress alongside rhythm care. NHLBI selected medicine review and arrhythmia support, March2022.
ECG, blood tests and amiodarone monitoring
A useful monitoring plan states what will be checked, why, who arranges it and how results will lead to a review. Kidney and electrolyte checks are relevant to sotalol and digoxin; ECG or other tests depend on the specific medicine and clinical question. “The medicine is working” and “the medicine remains safe” are different questions. NHS sotalol purpose and blood monitoring, August5,2025; NHS digoxin mechanism and selected monitoring, March22,2023, review overdue.
Amiodarone monitoring may assess thyroid, liver, heart, eye or lung concerns. The MHRA says routine lung imaging is unnecessary during long-term treatment and recommends investigation when toxicity is suspected. A current hospital leaflet includes repeat chest-X-ray wording; that timetable is not adopted as a universal requirement here. Ask which specialist plan applies. MHRA amiodarone safety and monitoring notice, updated May20,2026; CUH amiodarone leaflet, approved September22,2026 version9.
A symptom diary can help the team relate episodes to recordings and treatment changes. A consumer-device result can be useful information, but it cannot establish that a dose should be raised, a drug changed or an emergency ignored.
Public guidance provides clinical context. Complete original-trial funding and author relationships were not cleared for comparative efficacy, so no independent preferred-drug ranking or numerical recurrence promise is offered.
Proarrhythmia, organ toxicity and urgent symptoms
Seek emergency help for palpitations accompanied by fainting or marked faintness, chest pain, serious breathing difficulty, collapse or a severe allergic reaction. Do not drive yourself. The sotalol safety original specifically identifies palpitations with dizziness/faintness and chest pain as emergency warnings. NHS sotalol adverse effects and emergency warnings, August5,2025.
Digoxin can cause gastrointestinal symptoms, dizziness or visual changes, and new combinations of symptoms warrant prompt review for possible excess exposure or another problem. Do not diagnose toxicity by counting symptoms or dismiss a serious symptom because fewer than a particular number are present. NHS digoxin symptoms requiring review, March22,2023, review overdue.
With amiodarone, new/worsening breathlessness or persistent cough, jaundice, a markedly changed rhythm or loss of eyesight require urgent action. The MHRA patient advice includes a stop-and-seek-care instruction for specified serious symptoms; follow the medicine alert instructions and obtain immediate medical assessment. Routine advice to continue treatment is not an instruction to ignore such warnings. MHRA amiodarone safety and monitoring notice, updated May20,2026.
Amiodarone can also cause sun sensitivity and thyroid-related symptoms, and its effects can persist after stopping. The current CUH leaflet advises reporting concerns and discussing protection from sunlight. New blurred vision deserves review rather than an assumption that every eye effect is harmless. CUH amiodarone leaflet, approved September22,2026 version9.
Other prescriptions, pharmacy products and herbal interactions
Some combinations can affect rhythm, blood pressure or electrolyte balance. The sotalol original identifies selected antibiotics and antidepressants, other rhythm medicines, verapamil/diltiazem and medicines that lower potassium. These are examples rather than a complete interaction list. NHS sotalol medicine/supplement interactions, August5,2025.
Digoxin interactions can involve other heart medicines, diuretics, antibiotics, anti-inflammatory drugs and pharmacy products such as antacids or laxatives. St John’s wort can change its effect. Check the exact product with a pharmacist; do not stop a second necessary treatment merely because its class appears on a list. NHS digoxin medicine/herbal interactions, March22,2023, review overdue.
Amiodarone interacts with many medicines. The current CUH leaflet also highlights grapefruit and alcohol questions. Interactions can remain relevant after treatment stops, so retain it in the recent-medicine history until the team advises otherwise. CUH amiodarone leaflet, approved September22,2026 version9.
Tell every treating service about the complete list before a new prescription, admission or anaesthetic. A short antibiotic course or nonprescription product still merits a check.
Heart function, kidney health, breathing disease and pregnancy
Report a slow pulse, low blood pressure, worsening heart failure, kidney problems, breathing disease and relevant allergies before starting or reviewing treatment. These factors can alter suitability. The current NHS beta-blocker page treats breathing problems as a review issue; a blanket statement that every person with COPD must never receive any beta blocker is not adopted. NHS beta blockers, actual September4,2026 original.
Sotalol suitability also needs review if there is severe diarrhoea or other circumstances affecting electrolytes or kidney health. A previously tolerated prescription can need reassessment when health changes. Contact the service rather than independently increasing or skipping doses. NHS sotalol suitability factors, August5,2025.
Pregnancy and breastfeeding advice differs between rhythm medicines. NHS sotalol information describes circumstances where specialist use may be possible and notes limited lactation data. Arrange a cardiac/maternity review before changing treatment; absence of known harm is not proof of no risk. NHS sotalol pregnancy/lactation discussion, August5,2025.
Children and people with inherited rhythm conditions need appropriate specialist care. An adult medicine page or another family member’s regimen does not provide a paediatric prescription.
Written prescriptions, missed doses and procedure planning
This guide provides no loading, maintenance or “pill-in-the-pocket” regimen. Some selected patients may receive a clinician-defined episode plan, but it requires the diagnosed rhythm, suitability review and exact instructions. Never invent an extra dose from the pulse rate.
Use the actual prescription and leaflet for missed doses and administration. Do not double a forgotten sotalol dose. If more than prescribed was taken, obtain urgent advice; a slow heartbeat or breathing difficulty after excess sotalol requires emergency assessment. NHS sotalol prescription, continuity and overdose context, August5,2025.
Do not make routine abrupt changes because symptoms improve or mild adverse effects are troublesome. Ask for review and a clear change plan; serious warning symptoms require urgent action as described above. Arrange repeat supplies before they run out. NHS sotalol prescription, continuity and overdose context, August5,2025.
Before surgery or anaesthesia, tell the team about rhythm medicines. The prescriber and procedure team should coordinate any change. There is no universal stop interval here. NHS selected sotalol mechanism and procedure questions, August5,2025.
Laboratory electrical effects versus human outcomes
Cell and animal experiments on vessel function or cardiac stress can suggest mechanisms. They do not establish safe human dosing, symptom improvement or fewer serious events. A laboratory preparation and a retail product may differ in composition, absorption and exposure. No animal or in-vitro result contributes to the independent clinical verdict in this guide.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 20 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Producers/distributors earn from marketed rhythm medicines and associated products. National NHS and separate CUH provider finance, NHLBI budget/gift authority and MHRA public/industry-fee funding were actually checked. Institution funding does not identify a page sponsor or clear every original drug trial. No maker outcome claim or unsupported comparative drug ranking determines this guide.
A medicine’s generic ingredient name is separate from the ownership and financial interests of specific marketed products. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI selected AF rate, rhythm and clot-prevention distinctions, November2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual dated2022 original body read. Stable mechanism, diagnostic and follow-up framework only; not an exhaustive2026 drug/procedure menu. Blanket COPD/beta-blocker bans, sodium-blocker/all-heart-disease generalization, universal treatment sequence, device indication/driving/exercise rules and outcome rates excluded. Public-care accuracy incentive; exact author, source allocation and original trial finance unclosed. Role: Selected rate/rhythm/clot-prevention distinctions; simplified contraindication/menu claims excluded. |
| NHLBI arrhythmia medicine/procedure mechanisms, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual dated2022 original body read. Stable mechanism, diagnostic and follow-up framework only; not an exhaustive2026 drug/procedure menu. Blanket COPD/beta-blocker bans, sodium-blocker/all-heart-disease generalization, universal treatment sequence, device indication/driving/exercise rules and outcome rates excluded. Public-care accuracy incentive; exact author, source allocation and original trial finance unclosed. Role: Mechanism families and separate procedure/device context. |
| NHLBI rhythm diagnosis and selected monitoring tests, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual dated2022 original body read. Stable mechanism, diagnostic and follow-up framework only; not an exhaustive2026 drug/procedure menu. Blanket COPD/beta-blocker bans, sodium-blocker/all-heart-disease generalization, universal treatment sequence, device indication/driving/exercise rules and outcome rates excluded. Public-care accuracy incentive; exact author, source allocation and original trial finance unclosed. Role: Clinical rhythm identification and tests. |
| NHLBI selected medicine review and arrhythmia support, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actual dated2022 original body read. Stable mechanism, diagnostic and follow-up framework only; not an exhaustive2026 drug/procedure menu. Blanket COPD/beta-blocker bans, sodium-blocker/all-heart-disease generalization, universal treatment sequence, device indication/driving/exercise rules and outcome rates excluded. Public-care accuracy incentive; exact author, source allocation and original trial finance unclosed. Role: Follow-up, symptom review, medicine lists and support. |
| NHS beta blockers, actual September4,2026 original | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual September4,2026 original read; attributed medicine purpose, safety and monitoring only. Public-care accuracy/accountability incentives; named contributors, page allocation and underlying drug-trial finance unclosed. No independent efficacy ranking, personal dose or universal review timetable. Role: Actual September2026 beta-blocker purpose and suitability review. |
| NHS sotalol purpose and blood monitoring, August5,2025 | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual August5,2025 original read; attributed medicine purpose, safety and monitoring only. Public-care accuracy/accountability incentives; named contributors, page allocation and underlying drug-trial finance unclosed. No independent efficacy ranking, personal dose or universal review timetable. Role: Sotalol selected purpose, kidney/electrolyte monitoring. |
| NHS selected sotalol mechanism and procedure questions, August5,2025 | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual August5,2025 original read. Selected mechanism, blood monitoring, procedure coordination only. General long-term-safety, universal sports/contraception clearance, fixed washout, salt-causality and dosing/onset claims excluded. Public-care accountability; underlying trial/author finance unclosed. Role: Selected mechanism, procedure and clinical-choice context. |
| NHS sotalol adverse effects and emergency warnings, August5,2025 | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual August5,2025 original read; attributed medicine purpose, safety and monitoring only. Public-care accuracy/accountability incentives; named contributors, page allocation and underlying drug-trial finance unclosed. No independent efficacy ranking, personal dose or universal review timetable. Role: Palpitations/faintness/chest-pain and allergy warnings. |
| NHS sotalol medicine/supplement interactions, August5,2025 | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual August5,2025 original read; attributed medicine purpose, safety and monitoring only. Public-care accuracy/accountability incentives; named contributors, page allocation and underlying drug-trial finance unclosed. No independent efficacy ranking, personal dose or universal review timetable. Role: Interacting medicines and supplement uncertainty. |
| NHS sotalol suitability factors, August5,2025 | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual August5,2025 original read; attributed medicine purpose, safety and monitoring only. Public-care accuracy/accountability incentives; named contributors, page allocation and underlying drug-trial finance unclosed. No independent efficacy ranking, personal dose or universal review timetable. Role: Kidney, slow-rate, heart-failure and breathing-risk review. |
| NHS sotalol prescription, continuity and overdose context, August5,2025 | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual August5,2025 original read; attributed medicine purpose, safety and monitoring only. Public-care accuracy/accountability incentives; named contributors, page allocation and underlying drug-trial finance unclosed. No independent efficacy ranking, personal dose or universal review timetable. Role: Continuity, overdose and actual-prescription context; numerical doses excluded. |
| NHS sotalol pregnancy/lactation discussion, August5,2025 | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual August5,2025 original read; attributed medicine purpose, safety and monitoring only. Public-care accuracy/accountability incentives; named contributors, page allocation and underlying drug-trial finance unclosed. No independent efficacy ranking, personal dose or universal review timetable. Role: Individual maternity/lactation review; limited evidence not harm absence. |
| NHS digoxin mechanism and selected monitoring, March22,2023, review overdue | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual March22,2023 original read, March2026 next-review date overdue. Selected mechanism, symptoms and interaction caution only; response-time claims, numerical event frequencies, universal fluid/driving assurances and side-effect-count toxicity diagnostic rule excluded. Public-care accuracy incentive; page/contributor/original-trial finance unclosed. Role: Selected digoxin purpose and kidney/electrolyte context. |
| NHS digoxin symptoms requiring review, March22,2023, review overdue | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual March22,2023 original read, March2026 next-review date overdue. Selected mechanism, symptoms and interaction caution only; response-time claims, numerical event frequencies, universal fluid/driving assurances and side-effect-count toxicity diagnostic rule excluded. Public-care accuracy incentive; page/contributor/original-trial finance unclosed. Role: New gastrointestinal/vision/rhythm symptoms and review. |
| NHS digoxin medicine/herbal interactions, March22,2023, review overdue | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual March22,2023 original read, March2026 next-review date overdue. Selected mechanism, symptoms and interaction caution only; response-time claims, numerical event frequencies, universal fluid/driving assurances and side-effect-count toxicity diagnostic rule excluded. Public-care accuracy incentive; page/contributor/original-trial finance unclosed. Role: Medicine, pharmacy-product and StJohn’swort cautions. |
| CUH amiodarone leaflet, approved September22,2026 version9 | Cambridge University Hospitals NHS Foundation Trust: actual2025–26 audited accounts documents NHS commissioner, private-patient, research/training, donation and other service income. NIHR infrastructure and industry/charity research channels disclosed; exact leaflet allocation, contributor/original-drug-trial financial chain unresolved. | United Kingdom; Cambridge University Hospitals, Addenbrooke’s/TheRosie, HillsRoad, Cambridge, England; actual original contact checked. | Tier 2 provider clinical education; mixed institutional finance disclosed, page/author/drug-trial chain unclassified. | C provisional — actual September22,2026 version9 original body and contact read; search index still displayed2023 version8 and was not substituted. Selected skin/vision/thyroid/interactions/continuity education only. Fixed doses, universal repeat imaging/eye-test schedules, guaranteed reversibility and blanket pregnancy exception rules excluded; MHRA says routine lung imaging unnecessary. Specialist service accountability; page allocation/contributor/original drug-trial finance unclosed. Role: Actual September2026 selected leaflet education; fixed imaging schedule excluded. |
| MHRA amiodarone safety and monitoring notice, updated May20,2026 | Actual 2025–26 statutory accounts printed pp76–77 report £175.6m trading income from statutory industry regulatory fees and nonstatutory customer goods/services, plus £82.7m DHSC grant-in-aid recorded as taxpayers’ equity rather than operating income. Licence/vigilance/inspection/device fees, clinical-trial regulatory work, CPRD data-access licences and biological standards/services are described; p145 fee context read. Actual MHRA accounts. Complete named fee-payers, source-page allocation and supporting trial/author finances remain unclosed; regulator fees are not proof a particular company financed a notice. | United Kingdom; actual report printed p4 gives 10 South Colonnade, Canary Wharf, London, England. Full fee-payer jurisdictions unresolved. | Tier 2 fee-and-public-funded regulator safety context, provisional; supporting trial finance unclassified | B provisional — actual2022 notice with May20,2026 brand/card-link update read. Regulatory toxicity, specialist supervision, symptom/action and routine-lung-imaging context only. Public-safety incentive and actual industry-fee reliance disclosed; original drug trial/author finances unresolved. No numeric efficacy, guaranteed reversibility or manufacturer superiority. Role: Actual updated notice, toxicity, symptom/action and lung-imaging advice. |
| CUH actual audited2025–26 accounts | Cambridge University Hospitals NHS Foundation Trust: actual2025–26 audited accounts documents NHS commissioner, private-patient, research/training, donation and other service income. NIHR infrastructure and industry/charity research channels disclosed; exact leaflet allocation, contributor/device-study financial chain unresolved. | United Kingdom; Cambridge University Hospitals, Addenbrooke’s/TheRosie, HillsRoad, Cambridge, England; actual original contact checked. | Tier 3 institutional financial self-report. | B provisional — actual197page audited institutional report read; statutory accountability, own reporting and no page allocation. Finance only. |
| MHRA annual report and accounts 2025–26, actual financial/contact passages | Actual 2025–26 statutory accounts printed pp76–77 report £175.6m trading income from statutory industry regulatory fees and nonstatutory customer goods/services, plus £82.7m DHSC grant-in-aid recorded as taxpayers’ equity rather than operating income. Licence/vigilance/inspection/device fees, clinical-trial regulatory work, CPRD data-access licences and biological standards/services are described; p145 fee context read. Actual MHRA accounts. Complete named fee-payers, source-page allocation and supporting trial/author finances remain unclosed; regulator fees are not proof a particular company financed a notice. | United Kingdom; actual report printed p4 gives 10 South Colonnade, Canary Wharf, London, England. Full fee-payer jurisdictions unresolved. | Tier 3 statutory institutional self-report | B provisional — actual original read; statutory public accountability and safety-surveillance incentives, with industry fee reliance and incomplete financial chains disclosed. Institutional finance/contact only; not independent medicine efficacy evidence. Role: Financial provenance only. |
| NHS England actual audited2025–26 accounts | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 3 institutional financial self-report. | B provisional for actual statutory financial channels; no page/trial allocation or complete donor chain. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
Frequently asked questions
Is rate control the same as rhythm control? No; the treatment goals differ.
Does a normal-feeling rhythm mean AF anticoagulation can stop? No automatic stop rule follows.
Can antiarrhythmic treatment worsen a rhythm? Yes; safety assessment and monitoring matter.
Does amiodarone always require regular chest X-rays? The regulator does not recommend routine lung imaging; follow the specialist plan.
Can supplements replace the prescription? No financially screened replacement is established here.
Can I take an extra tablet during palpitations? Only follow an explicit personal clinical plan; serious symptoms need urgent help.
Sources and funding notes
- NHLBI selected AF rate, rhythm and clot-prevention distinctions, November2022 — Selected rate/rhythm/clot-prevention distinctions; simplified contraindication/menu claims excluded.
- NHLBI arrhythmia medicine/procedure mechanisms, March2022 — Mechanism families and separate procedure/device context.
- NHLBI rhythm diagnosis and selected monitoring tests, March2022 — Clinical rhythm identification and tests.
- NHLBI selected medicine review and arrhythmia support, March2022 — Follow-up, symptom review, medicine lists and support.
- NHS beta blockers, actual September4,2026 original — Actual September2026 beta-blocker purpose and suitability review.
- NHS sotalol purpose and blood monitoring, August5,2025 — Sotalol selected purpose, kidney/electrolyte monitoring.
- NHS selected sotalol mechanism and procedure questions, August5,2025 — Selected mechanism, procedure and clinical-choice context.
- NHS sotalol adverse effects and emergency warnings, August5,2025 — Palpitations/faintness/chest-pain and allergy warnings.
- NHS sotalol medicine/supplement interactions, August5,2025 — Interacting medicines and supplement uncertainty.
- NHS sotalol suitability factors, August5,2025 — Kidney, slow-rate, heart-failure and breathing-risk review.
- NHS sotalol prescription, continuity and overdose context, August5,2025 — Continuity, overdose and actual-prescription context; numerical doses excluded.
- NHS sotalol pregnancy/lactation discussion, August5,2025 — Individual maternity/lactation review; limited evidence not harm absence.
- NHS digoxin mechanism and selected monitoring, March22,2023, review overdue — Selected digoxin purpose and kidney/electrolyte context.
- NHS digoxin symptoms requiring review, March22,2023, review overdue — New gastrointestinal/vision/rhythm symptoms and review.
- NHS digoxin medicine/herbal interactions, March22,2023, review overdue — Medicine, pharmacy-product and StJohn’swort cautions.
- CUH amiodarone leaflet, approved September22,2026 version9 — Actual September2026 selected leaflet education; fixed imaging schedule excluded.
- MHRA amiodarone safety and monitoring notice, updated May20,2026 — Actual updated notice, toxicity, symptom/action and lung-imaging advice.
- CUH actual audited2025–26 accounts — Financial provenance only.
- MHRA annual report and accounts 2025–26, actual financial/contact passages — Financial provenance only.
- NHS England actual audited2025–26 accounts — Financial provenance only.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. Actual NHLBI arrhythmia treatment/diagnosis/livingMarch24,2022 and AF treatmentNovember30,2022 bodies read for selected distinctions only; blanket COPD, sodium-blocker contraindication and all-procedure sequence/generalization excluded. Actual NHS beta-blockerSeptember4,2026 body read. Actual sotalolAugust5,2025 about/questions/harms/interactions/who/use/pregnancy originals read; dosing/onset/washout, universal activity/contraception, fluid and long-term-safety assurances excluded. Actual digoxinMarch22,2023 about/harms/interactions read with overdueMarch2026 review disclosed; no symptom-count diagnostic rule or universal fluid/driving advice. Actual CUHamiodaroneSeptember22,2026 version9 body/contact read; searchindex2023 version8 notsubstituted. Actual MHRA2022 safety notice updatedMay20,2026 read; selected symptom/action and no-routine-lung-imaging advice used, fixed hospital repeat-imaging/eye schedules and reversibility guarantees excluded. Actual NHSE/CUH2025–26 finances,NHLBIbudget/giftauthority and MHRA2025–26 finance/contact read previously this run. Complete originaldrugtrial/contributor finance unclosed. No personal dose/episode regimen, emergency injection protocol, current exhaustive international drug menu or independent efficacy ranking. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.